Kidney Cancer Symposium | Conference

Underreporting of Immunotherapy-Related AEs a Concern in RCC

January 24th 2017

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

Expert Discusses 2-Year Update of Pivotal Nivolumab RCC Trial

January 24th 2017

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Researcher Hopes Vaccines Can Improve Immunotherapy Outcomes in RCC

January 23rd 2017

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

Rini Stresses Axitinib Remains Significant in RCC

January 20th 2017

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Dr. Touijer on Surgical Options for Patients with RCC

November 9th 2016

Karim A. Touijer, MD, MPH, surgeon, Memorial Sloan Kettering Cancer Center, discusses the considering factors for surgical options for patients with renal cell carcinoma (RCC).

RECORD-3 Molecular Analysis Characterizes Poor-Risk Patients With mRCC

November 8th 2016

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Dr. Hsieh on Patient Characterization From RECORD-3 Study in Metastatic RCC

November 8th 2016

James J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.

Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCC

November 8th 2016

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

Lenvatinib Regimen Setting Pace for Emerging Combos in Kidney Cancer

November 6th 2016

The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.

RCC Experts Consider Immunotherapy Integral to Optimizing Adjuvant Care

November 5th 2016

Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.

Cabozantinib Benefits Similar in MET Expressing Advanced RCC

November 5th 2016

Cabozantinib demonstrated consistent benefits compared with everolimus for patients with advanced, pretreated renal cell carcinoma in a subgroup analysis of the phase III METEOR trial that explored MET expression.

Dr. Hutson on Lenvatinib/Everolimus Combo in RCC

November 5th 2016

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCC

November 5th 2016

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

Expert Examines Conflicting Adjuvant RCC Results

November 5th 2016

Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.

Dr. Plimack on Significance of CheckMate-025 Trial in RCC

November 5th 2016

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Expert Discusses Neoadjuvant Treatment Potential in Advanced RCC

November 5th 2016

Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.

Novel Targeted Agents in Development, But Will Compete With Immunotherapy in RCC

November 5th 2016

Toni K. Choueiri, MD, dives into the ongoing research with volitinib, the competing yet complementary roles of targeted agents and immunotherapy, and the most important steps to take with biomarker research in the field of renal cell carcinoma.

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC

November 5th 2016

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).